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Lactate dehydrogenase (LDH) is an essential metabolic
enzyme that catalyzes the interconversion of pyruvate and
lactate using NADH/NAD+ as a co-substrate. Many cancer
cells exhibit a glycolytic phenotype known as the Warburg
effect, in which elevated LDH levels enhance the conversion
of glucose to lactate, making LDH an attractive therapeutic
target for oncology. Two known inhibitors of the human
muscle LDH isoform, LDHA, designated 1 and 2, were
selected, and their IC50 values were determined to be 14.4 
3.77 and 2.20  0.15 mM, respectively. The X-ray crystal
structures of LDHA in complex with each inhibitor were
determined; both inhibitors bind to a site overlapping with the
NADH-binding site. Further, an apo LDHA crystal structure
solved in a new space group is reported, as well as a complex
with both NADH and the substrate analogue oxalate bound in
seven of the eight molecules and an oxalate only bound in the
eighth molecule in the asymmetric unit. In this latter structure,
a kanamycin molecule is located in the inhibitor-binding site,
thereby blocking NADH binding. These structures provide
insights into LDHA enzyme mechanism and inhibition and
a framework for structure-assisted drug design that may
contribute to new cancer therapies.
PDB references: LDHA, apo, 
4ojn; complex with 
compound 1, 4qt0; complex 
with compound 2, 4qsm; 
complex with oxalate and 
NADH or kanamycin, 4okn
1. Introduction
Lactate dehydrogenase (LDH) is an oxidoreductase enzyme
that plays a central role in metabolism. LDH catalyzes the
reversible conversion of the substrate pyruvate to lactate with
the concomitant conversion of NADH, a ‘co-substrate’, to
NAD+. LDH, which is present in organisms ranging from
bacteria to humans, is active as a tetramer. There are two
major forms of LDH in humans: LDHA, encoded by the
LDHA gene, is a homotetramer present in skeletal muscle
(M4) and liver, and LDHB, encoded by the LDHB gene, is
a homotetramer found in heart tissue (H4). The catalytic
mechanism is conserved among isoforms and within species.
First NADH and then pyruvate bind to an active-site cleft,
inducing the closure of an active-site loop to seal the catalytic
site from free solvent. Arg105 in the active-site loop clamps
down on the bound pyruvate. A hydride ion is then trans-
ferred from the nicotinamide ring of NADH to the carbonyl O
atom of pyruvate, with His193 acting as a catalytic general acid
(Dunn et al., 1991).
LDH has been implicated as a potential therapeutic target
in oncology (Koukourakis et al., 2003, 2005, 2006). Many
tumours and cancer cells exhibit the Warburg effect, in which
ATP is produced mainly via aerobic glycolysis, a metabolic
pathway concluding with the LDH-catalyzed conversion of
pyruvate to lactate (Vander Heiden, 2011; Warburg, 1956;
Hamanaka & Chandel, 2012; Fantin et al., 2006; Fiume et al.,
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2010; Le et al., 2010; Sheng et al., 2012; Wang et al., 2012; Xie
et al., 2009, 2014). Knockdown of LDHA by shRNA or inhi-
bition by a small molecule results in oxidative damage and
death of cancer cells (Granchi, Roy, Giacomelli et al., 2011;
Granchi, Roy, Mottinelli et al., 2011). Thus, small-molecule
LDH inhibitors are actively being sought to exploit this
aberrant phenotype and block cancer-cell metabolism
(Billiard et al., 2013; Dragovich et al., 2013, 2014; Fauber et al.,
2013; Granchi et al., 2013; Kohlmann et al., 2013; Carruthers et
al., 2012; Manerba et al., 2012; Ward et al., 2012; Yang et al.,
2014).
Atomic structures of LDH have informed catalytic
mechanism and provide a foundation for the design of
inhibitory molecules as potential anticancer therapeutics.
Only a few apo LDH structures from eukaryotes have been
reported to date: LDH M4 from dogfish (PDB entry 6ldh;
Abad-Zapatero et al., 1987), LDH C4 from mouse testes (PDB
entry 2ldx; Hogrefe et al., 1987) and, most recently, human
muscle LDHA (PDB entry 4l4r; Dempster et al., 2014). Most
of the apo LDHA structures have an open conformation of
the active site, in which the mobile active-site loop, residues
95–110, is oriented away from the body of the enzyme,
allowing free diffusion of substrate and co-substrate into the
extended ligand-binding groove. An exception is the mouse
apo LDH C4 structure, in which the active-site loop is closed
in each of the four molecules in the tetrameric asymmetric unit
(PDB entry 2ldx; Hogrefe et al., 1987). Just as the apo struc-
ture is not always crystallized in an open conformation, the
presence of ligand in the active site does not necessarily result
in closure. NADH-bound human LDHA structures have an
open conformation (PDB entry 4l4s; Dempster et al., 2014),
and ternary complexes with NADH and the pyruvate
analogue oxamate can be closed, as in the octameric asym-
metric unit of pig LDH (PDB entries 9ldb and 9ldt; Dunn et
al., 1991), or a combination of open and closed forms, as in the
human and rabbit LDHA ternary structures (PDB entries 1i10
and 3h3f; Read et al., 2001; Swiderek et al., 2009). Collectively,
these structural variations suggest that (i) ligand binding can
occur without active-site loop closure and that (ii) the active-
site loop is dynamic and switches between the open and closed
conformation both in the absence and the presence of ligand.
A number of crystal structures have been reported for
mammalian LDH in complex with small-molecule inhibitors
identified by screening compound libraries (Dragovich et al.,
2013; Fauber et al., 2013; Kohlmann et al., 2013; Ward et al.,
2012). These include pyrazine-based and pyrimidine-based
inhibitors that bind in the active-site cleft simultaneously with
NADH co-substrate (Dragovich et al., 2013; Fauber et al.,
2013), and those designed to span the active site using a
fragment-based drug-discovery approach (Kohlmann et al.,
2013; Ward et al., 2012). As part of our interest in developing
LDHA inhibitors to modulate cancer-cell metabolism, we
characterized two known quinoline-based inhibitors of human
LDHA (Chai et al., 2012) and obtained X-ray crystal struc-
tures of the LDHA–inhibitor complexes. We also report a new
apo LDHA structure solved in a different space group to that
reported previously (Dempster et al., 2014) plus a ternary
complex with NADH and the substrate analogue oxalate, in
which the NADH in one of the eight molecules in the asym-
metric unit is replaced by kanamycin. We discuss the impli-
cations of these structures for enzyme mechanism and
inhibitor design.
2. Materials and methods
2.1. Cloning and expression of LDHA
The human LDHA gene encoding a C-terminal hexa-
histidine tag was synthesized by GeneArt (Life Technologies)
based on GenBank locus CAG46515 with codon usage
adapted to Escherichia coli. The gene was inserted into the
pET-29b expression vector (Novagen) using NdeI/XhoI sites,
which results in a His tag appended to the C-terminus of
LDHA. The gene sequence was verified and the resulting
pET-29b-LDHA vector was introduced into E. coli
BL21(DE3) cells (Stratagene) by transformation following
the manufacturer’s protocol. Cells containing the LDHA
vector were selected by overnight growth on Luria–Bertani
(LB) agar plates containing 50 mg ml1 kanamycin at 37C. A
single colony was picked from the plate and grown at 37C
overnight in LB broth containing 50 mg ml1 kanamycin (LB-
kan) to obtain a starter culture. A 10 ml aliquot of the starter
culture was introduced into 1 l LB-kan and grown at 37C with
shaking to an optical density of between 0.6 and 1 at 600 nm.
Protein expression was induced with 0.025 mM isopropyl -d-
1-thiogalactopyranoside (IPTG) and the cells were grown for
a further 23 h at room temperature. The cells were harvested
by centrifugation (4960g, 10 min, 4C) and stored as a pellet at
80C until use.
2.2. LDHA purification
Frozen cell pellets from 2 l culture were suspended in buffer
A (20 mM NaH2PO4/Na2HPO4 pH 7.5, 100 mM NaCl) plus
protease-inhibitor cocktail tablets (EDTA-free, Roche).
Lysozyme was added to a final concentration of 2 mg ml1 and
the suspension was gently stirred at room temperature for 1 h
followed by sonication to lyse the cells. Intact cells and inso-
luble material were removed by centrifugation at 40 000g and
4C for 60 min. The supernatant was filtered using a 0.4 mm
membrane and loaded onto an Ni–NTA column pre-equili-
brated with buffer A containing 30 mM imidazole. The Ni–
NTA column was washed with 20 column volumes of buffer A
and the protein was eluted with 300 mM imidazole pH 7.5
in buffer A. The eluted protein was dialyzed exhaustively
in 100 mM HEPES pH 7.5 and centrifuged at 5000g and 4C
for 30 min to remove insoluble material. The protein was
concentrated using an Amicon Ultra-15 filter unit (10 000 Da
molecular mass cutoff, Millipore) and further purified using a
HiPrep 16/60 Sephacryl S-300 HR size-exclusion column (GE
Life Sciences) pre-equilibrated with 100 mM HEPES pH 7.5.
LDHA eluted as a tetramer and was estimated by SDS–PAGE
to be greater than 95% pure. LDHA was concentrated to
25 mg ml1 using an Amicon Ultra-15 filter with a 10 000 Da
molecular-mass cutoff membrane, flash-frozen in liquid
nitrogen and stored at 80C.
2.3. Inhibitor synthesis
3-{[3-Carbamoyldimethoxypyrimidin-7-(2,4-dimethoxypyr-
imidin-5-yl)quinolin-4-yl]amino}benzoic acid (compound 1)
and 3-{[7-(2,4-dimethoxypyrimidin-5-yl)-3-sulfamoylquinolin-
4-yl]aminobenzoic acid (compound 2) were prepared
according to the procedures reported by Chai et al. (2012).
2.4. Inhibition assays
2.4.1. Absorbance assay. Compounds
1 and 2 were dissolved at 20 mM in
dimethyl sulfoxide (DMSO) and
working stocks were prepared in assay
buffer [phosphate-buffered saline
(PBS) containing 0.001% Triton and
20%(v/v) DMSO] through serial dilu-
tion. Assay buffer was added to wells of
a standard 96-well assay plate stamped
with NADH and LDHA (final concen-
trations: 500 mM NADH, 1 nM LDHA)
and incubated for 5 min at room
temperature. Inhibitor solutions were
added to all wells (final DMSO content:
2%) and the mixtures were incubated
for 5 min at room temperature. A solu-
tion of pyruvate (final concentration:
1 mM) was added to each well and the
consumption of NADH was monitored
through the decrease in absorbance
(340 nm) over 10 min at 37C using a
Molecular Devices SpectraMax 250
reader. The Ki values for compound 2
were determined using the same
procedure with fixed inhibitor concen-
trations ranging between 0 and 2.5 mM,
and pyruvate or NADH were varied in a
systematic fashion. The mode of inhi-
bition was determined by using a Line-
weaver–Burk plot to display the data,
and the Ki value was obtained using
GraphPad Prism to obtain the best fit.
2.4.2. Fluorescent assay. Inhibitor
dilutions were prepared as described for
the absorbance assay. Assay buffer was
added to one column (n = 3) of a stan-
dard 96-well plate containing inhibitor
solutions (final DMSO content: 2%).
LDHA and NAD+ in assay buffer (final
concentrations: 300 pM LDHA and
150 mM NAD+) were added to the
remaining wells and the mixtures were
incubated for 10 min at room tempera-
ture. A solution of lactate, resazurin and
diaphorase (final concentrations:
0.2 mM lactate, 0.625 mM resazurin, 0.04 U ml1 diaphorase)
in assay buffer was added to all wells and the mixtures were
incubated for 30 min at room temperature. Stop solution
(25 mM oxamate in assay buffer) was added to each well and
the fluorescence intensity was measured at 571 nm (excita-
tion)/590 nm (emission) on a BioTek Synergy H4 reader.
2.5. Protein crystallization
LDHA crystals were grown by the hanging-drop vapour-
diffusion method at 20C. Initial crystallization conditions
Table 1
Data-collection and refinement statistics for LDHA structures.
Values in parentheses are for the last shell.
Apo LDHA
LDHA–oxl–
NADH/kan LDHA–1 LDHA–2
Data statistics
Beamline SSRL 7-1 SSRL 7-1 SSRL 7-1 SSRL 7-1
Wavelength (Å) 1.0 1.0 1.0 1.0
Space group P3121 P212121 P3121 P3121
a, b, c (Å) 147.1, 147.1, 333.2 65.6, 159.6, 266.2 147.2, 147.2, 334.6 147.3, 147.3, 334.5
, ,  () 90.0, 90.0, 120.0 90.0, 90.0, 90.0 90.0, 90.0, 120.0 90.0, 90.0, 120.0
Resolution (Å) 2.4 2.1 3.2 3.0
Completeness (%) 99.5 (97.2) 99.9 (100.0) 99.6 (100) 99.9 (99.9)
No. of observed reflections 1175796 898093 515938 629385
No. of unique reflections 162753 163531 69933 84925
Rp.i.m.† (%) 8.6 (64.2) 9.9 (82.1) 7.0 (48.0) 5.8 (39.8)
hI/(I)i 22.8 (2.9) 14.4 (2.1) 13.7 (1.9) 14.6 (2.2)
Wilson B value (Å2) 44.0 37.7 57.9 52.1
Refinement statistics
Resolution limits (Å) 20.0–2.4 34.0–2.1 35.0–3.2 35.0–3.0
Z 48 32 48 48
No. of reflections used 154614 155268 66105 80339
Rcryst‡ (%) 21.3 20.6 17.2 16.7
Rfree§ (%) 25.0 24.5 27.1 24.7
No. of atoms
Protein 21083 20544 21017 20814
Ligands 146 434 264 272
Water 527 775 24 60
Average B factor (Å2)
Protein
Chain A 30.5 28.8 65.3 61.2
Chain B 28.8 28.1 75.1 63.6
Chain C 28.4 25.9 65.0 60.7
Chain D 29.2 23.7 68.8 60.9
Chain E 36.1 28.9 87.0 81.3
Chain F 28.2 30.4 70.3 65.7
Chain G 25.3 29.6 67.9 61.0
Chain H 32.3 35.0 79.7 73.2
Ligands
Glycerol 58.6 — — —
PEG 400 45.9 — — —
NADH — 31.0 — —
Oxalate — 28.3 — —
Sulfate — 42.4 — —
Kanamycin — 62.9 — —
1 — — 67.8 —
2 — — — 66.2
Water oxygen 32.5 33.6 47.5 47.0
R.m.s.d., bond lengths (Å) 0.008 0.007 0.014 0.011
R.m.s.d., bond angles () 1.32 1.27 1.78 1.55
Ramachandran plot
Favoured (%) 97.6 97.3 92.2 95.7
Allowed (%) 2.1 2.5 6.8 3.8
Outlier (%) 0.2 0.2 1.0 0.5
PDB code 4ojn 4okn 4qt0 4qsm
† Rp.i.m. =
P
hklf1=½NðhklÞ  1g
1=2 P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ. ‡ Rcryst =
P
hkl

jFobsj  jFcalcj

=P
hkl jFobsj. § Rfree is the cross-validation R factor for 5% of the reflections against which the model was not refined.
were obtained from the high-throughput screening laboratory
at the Hauptman–Woodward Medical Research Institute
(Luft et al., 2003). Apo LDHA crystals were grown by mixing
2 ml 25 mg ml1 LDHA with 2 ml reservoir solution consisting
of 100 mM bis-tris propane pH 7.0, 20%(v/v) PEG 400,
100 mM LiCl. LDHA–NADH crystals were grown by first
incubating 25 mg ml1 LDHA with NADH (3 mM) for 2 h at
4C and then setting up 4 ml drops with a 2:1:1 volume ratio of
LDHA–NADH, reservoir solution [18%(w/v) PEG 3350,
50 mM HEPES pH 6.8] and Silver Bullets Bio Screen 1
reagent A1 [Hampton Research; 0.16%(w/v) l-citrulline,
0.16%(w/v) l-ornithine hydrochloride, 0.16%(w/v) urea,
0.16%(w/v) oxalic acid, 0.16%(w/v) kanamycin monosulfate,
0.16%(w/v) l-arginine, 0.02 M HEPES sodium pH 6.8]. The
oxalate and kanamycin found in the LDHA ternary complex
were derived from reagent A1. Apo and NADH-bound
LDHA crystals appeared after three weeks. LDHA–inhibitor
complex crystals were obtained by adding 10 ml soaking
solution [20 mM inhibitor, 100 mM HEPES pH 7.5, 50 mM
LiCl, 100 mM bis-tris propane pH 7.0, 20%(v/v) DMSO,
25% PEG 8000] to 2 ml hanging drops containing apo LDHA
crystals and allowing the crystals to sit at room temperature
Figure 1
Human apo LDHA structure. (a) Apo LDHA chain A is shown in (a) cartoon and (b) surface representations, with the extended N-terminus coloured
grey and the large and small domains coloured cyan and green, respectively. The active-site cleft is framed by 6 and the 6–7 loop on the small domain
side and by the active-site loop between 4 and 3 on the large domain side. The polyethylene glycol 400 (PEG) molecule is shown in stick
representation with its C atoms coloured yellow and its O atoms coloured red. (c) The apo LDHA octamer, which is a dimer of tetramers joined by
interactions between the active-site loops of chains A and G and chains B and H. The twofold symmetry axis is indicated with a black spot. (d) Space-
filling representation of the apo LDHA octamer chain B coloured cyan to shown the extended conformation at the N-terminus. (e) Superposition of the
eight molecules in the asymmetric unit of the apo LDHA structure. The maximum r.m.s.d. between each chain and chain A is 0.65 Å (main-chain atoms).
for 24 h. All crystals were cryocooled in liquid nitrogen for
storage and transport to the Stanford Synchrotron Radiation
Lightsource (SSRL) for X-ray diffraction data collection.
2.6. Data collection, processing and structure determination
X-ray diffraction data for LDHA crystals were collected at
100 K on beamline 7-1 at SSRL using the Blu-Ice software
(González et al., 2008). The raw data were processed, inte-
grated and scaled using XDS (Kabsch, 2010). Matthews
coefficient calculations (Matthews, 1968) indicated that all
crystals contained eight molecules in the asymmetric unit, with
water contents of 65% for apo LDHA, 46% for LDHA–
NADH and 65% for the complexes of LDHA with both
compound 1 (LDHA–1) and compound 2 (LDHA–2). Struc-
tures were determined by the molecular-replacement method
using Phaser (McCoy et al., 2007) and refined using REFMAC
(Murshudov et al., 2011) in the CCP4 suite (Winn et al., 2011).
The apo LDHA structure was solved using the structure of
human LDHA in complex with NADH and oxamate (PDB
entry 1i10; Read et al., 2001) as the search model. Phaser gave
two unique solutions with high Z-scores. Several cycles of
rigid-body refinement were performed followed by refinement
with noncrystallographic symmetry restraints using REFMAC.
Difference maps were generated and inspected in Coot
(Emsley & Cowtan, 2004), clearly indicating a conformational
difference in the active-site loop in the apo structure relative
to the search model PDB entry 1i10. Iterative cycles of model
building and refinement using REFMAC and Coot improved
the model and reduced the R values. Water O atoms and
ligands were located in Coot and verified by a composite
annealed OMIT map using the CNS suite of programs
(Brünger et al., 1998). The final 2.4 Å resolution structure,
which has an Rcryst of 0.213 and an Rfree of 0.250, was validated
using PROCHECK (Laskowski et al., 1993) and MolProbity
(Chen et al., 2010) (Table 1). The amino-acid sequence of
LDHA is numbered according to GenBank locus CAG46515.
A tetramer of the apo LDHA structure was used as a model
to solve the LDHA–NADH complex by molecular replace-
ment, yielding two solutions with Z-scores of 11.2 and 9.7.
Figure 2
Ternary LDHA crystal structures. (a) The ternary LDHA octamer, which is a dimer of tetramers joined by interactions between the closed active-site
loops of chains A and G. Chains A, C, D, E, F, G and H have oxalate and NADH bound in the active site, while chain B has oxalate and kanamycin.
LDHA molecules are shown in cartoon representation and coloured by chain; ligands are shown as sticks with oxalate C atoms coloured green, NADH C
atoms coloured yellow and kanamycin C atoms coloured cyan. For all ligands, N atoms are coloured blue, O atoms are red and phosphates are orange. (b)
Closed chain A with oxalate (green C atoms) and NADH (yellow C atoms) and (c) open chain B with oxalate (green C atoms) and kanamycin (cyan C
atoms). LDHA is coloured grey with its active-site loop shown in orange.
After a few cycles of restrained refinement, the difference
maps were examined in Coot (Emsley & Cowtan, 2004),
revealing structural changes in the active-site loop relative to
apo LDHA and positive electron density for NADH in the
active sites of seven of the eight monomers in the asymmetric
unit. In addition, positive electron density matching oxalate
was found in all eight monomers. The active-site loop was
rebuilt using Coot (Emsley & Cowtan, 2004). After several
further cycles of restrained refinement, water O atoms were
located and the structures were further refined. The final
structure, which has a resolution of 2.1 Å, an Rcryst of 0.206
and an Rfree of 0.245, was validated using PROCHECK and
MolProbity (Laskowski et al., 1993; Chen et al., 2010; Table 1).
The apo LDHA tetramer was also used as a molecular-
replacement model for the LDHA–inhibitor structures. After
a few cycles of rigid-body refinement followed by further
cycles of restrained refinement with medium noncrystallo-
graphic symmetry restraints (NCS) restraints, weighted
‘difference’ maps (mFobs  DFcalc) were calculated. Differ-
ence maps contoured at 3.0 had density near the active-site
mobile loop, indicating the presence of inhibitor, in each of the
eight molecules in the asymmetric units of LDHA–1 and
LDHA–2. For refinement, SKETCHER in the CCP4 suite was
used to create inhibitor library descriptions. After iterative
cycles of restrained refinement, model adjustments and water
location, the complex structures were validated by
PROCHECK and MolProbity (Table 1). The final LDHA–1
structure has a resolution of 3.2 Å and Rcryst and Rfree values of
0.172 and 0.271, respectively. The LDHA–2 structure has a
resolution of 3.0 Å and Rcryst and Rfree values of 0.167 and
0.247, respectively.
3. Results
3.1. Human apo LDHA crystal structure
The human apo LDHA structure was solved at 2.4 Å
resolution. Apo LDHA crystallized in space group P3121 with
eight molecules in the asymmetric unit. The structure is
essentially identical to the recently published apo LDHA
structure (PDB entry 4l4r; Dempster et al., 2014), which
crystallized in space group P4122 with two molecules per
asymmetric unit. The 332-residue human LDHA is a globular
protein of mixed / secondary structure with a protruding
N-terminal segment (Figs. 1a and 1b). The LDHA active site
lies in an extended groove between two domains: a larger ‘co-
substrate-binding’ domain that has a Rossmann-type fold and
a smaller ‘substrate-binding’ domain. The active-site loop
(residues 95–110) is in an open
conformation.
Although these LDHA struc-
tures lack bound substrate and
co-substrate, they are not bona
fide apo structures owing to the
presence of a polyethylene glycol
(PEG 400), derived from the
crystallization conditions, in the
active site of all eight molecules
(Figs. 1a and 1b). PEG 400 fits
in a C-shape into the active site,
with its ends pointing outwards.
Three of the PEG 400 O atoms
are positioned to hydrogen bond
to Asp138 N2 and the remainder
of its interactions with LDHA are
hydrophobic. This molecule lies
adjacent to the substrate-binding
site and overlaps with the NADH
nicotinamide-binding site. The
presence of PEG 400 in the active
site appears to have no effect
on the LDHA structure, which
matches the published apo
LDHA structure with PDB code
4l4r [Dempster et al., 2014; root-
mean-square deviation (r.m.s.d.)
of 0.46 Å for backbone atoms of
chain A].
Apo LDHA crystallized as a
dimer of tetramers, with the
monomers within each tetramer
Figure 3
Interactions of oxalate and NADH in the ternary LDHA complex. (a, b) Solvent-excluded tunnel with
oxalate and NADH bound shown in two different views. LDHA is shown in grey space-filling
representation with its active-site loop coloured orange. Ligands are shown in stick representation, with
oxalate C atoms coloured green, NADH C atoms yellow, N atoms blue, O atoms red and phosphates
orange. (c) Interactions between oxalate and the LDHA substrate-binding site. Interacting side chains are
shown in stick representation. (d) Interactions between NADH and the co-substrate-binding site.
related by 222 symmetry and the two tetramers related by
twofold symmetry (Fig. 1c). Within each tetramer, the
extended N-terminus of each monomer makes pairwise
interactions with two adjacent molecules (Fig. 1d). All eight
molecules in the asymmetric unit are very similar in structure,
superimposing with a maximum r.m.s.d. of 0.69 Å for main-
chain atoms. Minor structural variations occur in the N-
terminal extensions between residues 13 and 18, and in the
active-site loops, which differ by as much as 2.8 Å for the C
positions of Glu102 at the apex of the loop (Fig. 1e). The
active-site loops mediate the only contacts between the two
tetramers in the asymmetric unit: the active-site loop of chain
A in tetramer 1 hydrogen bonds to that of chain G in tetramer
2, and reciprocal interactions are observed between chain H in
tetramer 2 and chain B in tetramer 1 (Fig. 1c). Glu102 of
chains A and H penetrates the active-site grooves of chains G
and B, respectively, but is oriented away from its partners for
chains G and B. Corresponding interactions occur between
chains C and E and chains D and F to link adjacent asym-
metric units in the crystal lattice.
3.2. Human LDHA ternary structures
In an attempt to determine a binary structure, we co-crys-
tallized LDHA with NADH and solved its structure to 2.1 Å
resolution in space group P212121. As with our apo LDHA
structure, the LDHA–NADH complex is a dimer of tetramers
(Fig. 2a). Electron density consistent with NADH was present
in the co-substrate-binding sites of seven of the eight mole-
cules (Fig. 2b). All eight molecules also had additional density
in the substrate-binding pocket consistent with oxalate (oxl), a
nonreactive analogue of the natural substrate pyruvate, in
which the methyl ketone group of pyruvate is replaced by a
carboxylate moiety (Figs. 2b and 2c). While oxalate was not
explicitly included in the crystallization setup, it is present
in reagent A1 of the Silver Bullets Bio Screen 1 (Hampton
Research). Thus, seven of the eight
molecules represent ternary structures
that closely match the published ternary
structures of human LDHA in complex
with NADH and oxamate (PDB entry
1i10; Read et al., 2001), which also
crystallized in space group P212121. The
active-site loop is closed in each of these
molecules. No NADH is present in the
eighth LDHA molecule (chain B), but
a kanamycin molecule (kan) is bound
near the active-site loop, overlapping
with the NADH-binding site (Fig. 2c).
In contrast to the closed LDHA–oxl–
NADH structures, the LDHA–oxl–kan
structure is in an open conformation.
The subunit–subunit interactions
within each tetramer are almost iden-
tical to those seen for the apo LDHA
tetramers. However, the closed confor-
mation for seven of the eight molecules
results in an asymmetric octamer in
which the two tetramers are tilted rela-
tive to each other and connected by
only two chains: A and G (Fig. 2a).
The closed conformation in the
LDHA–oxl–NADH structures seals the
binding-site cleft at the substrate-
binding end, creating a narrow tunnel-
like cavity in which the planar oxalate is
buried at the far end and the NADH
nicotinamide moiety is wedged tightly
between the oxalate and the floor of
the active-site cavity (Figs. 3a and 3b).
The pyrophosphate unit and adenosine
moiety of NADH are located at the
opening of the cavity. The interactions
between substrate, co-substrate and
LDHA have been described in detail
Figure 4
Interactions of oxalate and kanamycin in chain B of the ternary LDHA complex. (a) Close-up of
oxalate in the substrate-binding site. (b) Close-up of bound kanamycin. The corresponding sites in
(c) the ternary LDHA–oxl–NADH complex and (d) apo LDHA are shown for comparison. LDHA
is shown in a grey cartoon representation with its active-site loop coloured orange. Interacting side
chains are shown in stick representation, as are the ligands, with oxalate C atoms coloured green
and kanamycin C atoms coloured cyan. N atoms are shown in blue, O atoms in red and phosphates
in orange.
elsewhere (Dunn et al., 1991; Dempster et al., 2014). Briefly,
oxalate is held in the substrate-binding pocket by an extensive
network of planar hydrogen bonds and electrostatic contacts
to Asn138, Arg169, His193 and Thr248 (Fig. 3c). Arg106 at the
tip of the closed active-site loop clamps down on oxalate.
The nicotinamide ring of NADH stacks with the oxalate and
hydrogen-bonds to Asn138, Gln100, Ser161 and His193
(Fig. 3d). The side chain of the active-site loop residue Arg99
reaches across the active-site cleft, with its NH1 hydrogen
bonding to the NADH pyrophosphate. The NADH adenosine
lies in a hydrophobic pocket at the solvent-exposed end of the
closed active site, with its 20- and 30-hydroxyl groups hydrogen-
bonded to the side-chain carboxylate of Asp52.
Chain B of the ternary complex, which lacks NADH, is
highly similar to the NADH-bound chains, differing only in
having an open conformation (Figs. 2b and 2c). The oxalate
lies in the same position and shares the same planar hydrogen-
bond network as seen in the other
seven molecules in the asym-
metric unit, with the exception of
the missing Arg106 clamp, which
requires a closed active site to
engage (Fig. 4a). Kanamycin is
bound in a V-shape in the
hydrophobic pocket at the open
end of the active-site groove, with
its central aminocyclohexyl ring
penetrating the groove (Fig. 4b)
and overlapping with the
adenine-binding site of NADH
(Fig. 4c) and its two flanking
glycans pointing outwards.
Kanamycin, which, like oxalate,
originated from the Silver Bullet
crystallization solution, is not as
well resolved as the oxalate and
NADH ligands. Only minor
alterations in side-chain confor-
mation accompany kanamycin
binding, as the structure of chain
B is almost identical to that of the
apo LDHA structure (Fig. 4d).
Arg99 swings away to make room
for the kanamycin hydroxymethyl
glucopyranose ring and Arg112
hydrogen-bonds to one of the
hydroxyl groups on this ring,
disrupting the Arg112–Glu104
salt bridge seen in the apo LDHA
structure. Several hydrophobic
side chains contact kanamycin,
but their conformations are also
unchanged relative to the apo
structure. These include 3 helix
residues Ile116, Ile120 and
Phe119, the phenyl ring of which
stacks with the aminomethyl
glucopyranose ring of kanamycin. Thus, kanamycin binds to a
highly complementary site on LDHA and is likely to prevent
access of NADH by blocking the adenine-binding site.
3.3. Characterization of LDHA inhibitors
The two known inhibitors, compounds 1 and 2, were
analyzed for their ability to inhibit LDHA by measuring the
decrease in absorbance as NADH is converted to NAD+ upon
LDHA-catalyzed conversion of pyruvate to lactate. As shown
in Fig. 5(a), compounds 1 and 2 inhibit LDHA activity
moderately, with IC50 values of 14.4  3.77 and 2.20 
0.15 mM, respectively (Fig. 5a). The inhibition was also assayed
in the reverse direction of catalysis (with lactate as the
substrate) using a fluorescent-based coupled assay, which gave
IC50 values of 0.51  0.14 mM for compound 1 and 0.039 
0.007 mM for compound 2 (Fig. 5b). Ki values were determined
Figure 5
Quantification of LDHA inhibition by compounds 1 and 2. (a) Compounds 1 and 2 demonstrate moderate
inhibition of LDHA, as shown by an absorbance assay for the conversion of pyruvate to lactate. IC50 values
are 14.4  3.77 mM for compound 1 and 2.20  0.15 mM for compound 2. (b) Inhibition of the reverse
reaction, conversion of lactate to pyuvate, was measured using a fluorescence assay, producing IC50 values
of 0.51  0.14 mM for compound 1 and 0.039  0.007 mM for compound 2. (c) Lineweaver–Burk plots for
compound 2 to calculate Ki for NADH (Ki of 0.59  0.09 mM) and pyruvate (Ki of 2.52  0.21 mM).
for compound 2: the inhibition is
competitive with respect to
NADH (Ki of 0.59  0.09 mM)
and noncompetitive with respect
to pyruvate (Ki of 2.52 
0.21 mM) (Fig. 5c).
3.4. LDHA–inhibitor structures
Compounds 1 and 2 are shown
in Fig. 6(a). These compounds are
comprised of a central quinoline
heterocycle with a dimethox-
ypyrimidine attached at C3 and
an aminobenzoic acid at C6. They
differ in the C7 constituent, which
is an amide group in 1 and a
sulfonamide group in 2. LDHA–1
and LDHA–2 enzyme–inhibitor
complex structures were obtained
by soaking apo LDHA crystals in
solution containing 20 mM
compound 1 or 2 for 24 h, cryo-
cooling the crystals and collecting
X-ray diffraction data. LDHA–1
and LDHA–2 crystal structures
were solved to resolutions of 3.2
and 3.0 Å, respectively. Although
modest in resolution, the elec-
tron-density maps were refined
using NCS and showed clear
electron density to unambigu-
ously fit the ligands in each of the
eight molecules in the asymmetric
unit. The LDHA–inhibitor
complexes are highly similar to
each other and to the open apo
LDHA structure in terms of
crystal packing and atomic coor-
dinates. Compounds 1 and 2,
which are insoluble in aqueous
solution, interact with LDHA via
multiple hydrophobic contacts as
well as via salt bridges and
hydrogen bonds (Figs. 6b and 6c).
Both ligands occupy the same
binding site as kanamycin in the
LDHA–oxl–kan structure and
adopt V-shaped conformations
and LDHA contacts similar to
those of kanamycin (Figs. 6b, 6c,
6d and 4b). As with kanamycin, inhibitor binding involves
minimal adjustment in LDHA. Only the Arg99 side-chain
conformation is altered significantly: instead of moving out of
the way as it does for kanamycin, the Arg99 guanidinium
group stacks with the benzoate ring of 1 (Fig. 6b) and forms a
salt bridge with the carboxyl group of the benzoate of 2 in
some of the eight molecules in the asymmetric unit (Fig. 6c). In
both structures the Arg99 backbone amide also contacts the
benzoate carboxyl group via a hydrogen bond. Arg112 forms a
salt bridge with this same carboxyl group in both inhibitor
structures (Figs. 6b and 6c), but maintains its contacts with
Glu104 as in the apo LDHA structure (see Fig. 4d). The
Figure 6
Structures of LDHA bound to inhibitors 1 and 2. (a) Structures of 1 (3-{[3-carbamoyl-7-(2,4-
dimethoxypyrimidine-5-yl)quinolin-4-yl]amino}benzoic acid) and 2 (3-{[7-(2,4-dimethoxypyrimidine-5-
yl)-3-sulfamoylquinolin-4-yl]amino}benzoic acid). (b, c) Close-up of bound (b) 1 and (c) 2 showing
interactions with LDHA. LDHA is shown in a grey cartoon representation with its active-site loop
coloured orange. Interacting side chains are shown in stick representation, as are the inhibitors, with C
atoms coloured cyan. N atoms are blue, O atoms are red and S atoms are yellow. (d) Superposition of
kanamycin (cyan), 1 (yellow) and 2 (pink) as they are situated in the active site. (e) Superposition of chains
A and G in the octameric apo LDHA and LDHA–1 structures to show the change in the side-chain
conformation of Glu102 in chain A when 1 is bound to chain G. A similar interaction is observed in the
LDHA–2 octamer. Colours are as described for (b) and (c).
central quinoline rings of the inhibitors are sandwiched
between the hydrophobic side chains of Val53 and Ile116
and the dimethoxypyrimidines stack with Phe119. Asp52
hydrogen-bonds to the carbamoyl group in 1 and the sulfa-
moyl group in 2. An additional contact, in this case between
adjacent protein subunits in the octameric unit, occurs
between Glu102 at the tip of the active site of chains A and H
and the inhibitor in the adjacent chains G and B, respectively
(Fig. 5e). The Glu102 side chain is rotated relative to its
position in apo LDHA such that methylenes are inserted into
the hydrophobic crook of the V-shaped inhibitors. Reciprocal
interactions between chains G and A and chains B and H are
not observed, as the chain G and B active-site loops do not
insert into the active site of their partner chain.
4. Discussion
The human LDHA structures reported here, a new crystal
form of apo LDHA, a ternary complex with the substrate
inhibitor oxalate and NADH, a ternary structure with oxalate
and kanamycin, and binary structures with bound inhibitors 1
and 2, illustrate the ability of LDHA to bind to molecules with
only minimal rearrangements in its side chains. Productive
binding requires the presence of both pyruvate substrate and
NADH co-substrate and closure of the active-site loop to
exclude water molecules. In our oxalate/NADH-bound
structures the active-site loop is closed, but this is not the case
for all ternary structures (Read et al., 2001; Swiderek et al.,
2009). Furthermore, closed active sites have been observed for
apo LDH structures (Hogrefe et al., 1987). These results imply
a dynamic active-site loop that samples both conformations
regardless of the occupancy of the active site. Compounds
designed to restrict the movement/closure of this loop may
prove to be effective inhibitors for LDHA.
While our ternary LDHA–oxl–NADH structures are
closed, the single LDHA–oxl–kan structure is in an open
conformation, as are the LDHA–inhibitor complexes. Kana-
mycin and compounds 1 and 2 all bind to the same site, the
hydrophobic adenine-binding pocket at the exposed end of
the active-site groove. While the presence of these compounds
may restrict movement of the active-site loop, compounds
1 and 2 are likely to inhibit LDHA catalysis by preventing
NADH from binding. This mechanism is supported by our
competitive inhibition studies with compound 2, which show
that this inhibitor competes with NADH but not pyruvate.
To our knowledge, kanamycin has not been reported as an
LDHA inhibitor.
The molecular mimicry between kanamycin and inhibitors 1
and 2 is striking, with each molecule adopting a V-shaped
conformation and binding to the same set of residues at the
outermost portion of the active site. These inhibitors have
limited solubility and bind to LDHA via mostly hydrophobic
interactions. The adenine-binding site has been targeted by
other inhibitors alone and in combination with substrate
inhibitors (Kohlmann et al., 2013; Ward et al., 2012). Compared
with these inhibitors, for the most part, compounds 1 and 2
possess equal or better potency and are generally more drug-
like. The introduction of structural modifications to improve
pharmacokinetic properties and address metabolic liabilities
are the logical next steps to optimize these inhibitors.
Collectively, these structures further our understanding of
LDH catalysis and the insights into their active-site binding
provided by this study may aid the design of drug-like inhi-
bitors that could selectivity target the aberrant glycolytic
metabolism prevailing within many cancer cells and tumours.
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